Introduction
Integrins are a family of heterodimeric cell adhesion receptors, which not only mediate cell adhesion to extracellular matrix proteins but also transmit signals that are vital for anchoragedependent cell survival, proliferation, and motility (Hynes, 2002) . Thus, integrins play pivotal roles in physiological processes such as wound healing, immune responses, and hemostasis. Aberrant integrin signaling is also centrally involved in the development of human diseases such as thrombosis, cancer, and autoimmune diseases and is the target of many therapeutic agents (Hynes, 2002; Shattil and Newman, 2004) . Therefore, understanding the molecular events in the transduction of integrin signals is important in our understanding of many biological processes and has the potential to reveal novel intervention for diseases.
Integrin signaling is bidirectional in that ligand binding function of integrins requires conformational change in the extracellular ligand binding domain induced by intracellular signals (inside-out signaling), and ligand binding transduces outside-in signals that mediate cellular responses (Hynes, 2002; Vinogradova et al., 2002; Ginsberg et al., 2005; Wegener et al., 2007) . An early functional outcome of integrin outside-in signaling is cell spreading, which is characterized by the formation of fi lopodia and lamellipodia and represents the outward movement of cell membrane, polymerizing actin, and cytoskeletal complexes at the leading edge (Hall, 2005) . Integrin signaling later induces cell retraction, which is the inward movement of the cell membrane and cytoskeletal complexes, often at the rear end of cells. Coordinated spreading and retraction allows cell migration and in blood platelets facilitates stable platelet adhesion, thrombus formation, and consolidation. It has been shown that small GTP binding proteins Rac and cdc42 are involved in signaling mechanisms of cell spreading and that RhoA-mediated signaling is important in cell retraction (Hall, 2005) . However, it remains unclear how integrin signaling initiates and temporally regulates these two seemingly opposing cellular responses; this is a fundamental question in cell biology. In this study, we have discovered that calpain cleavage of β 3 at Tyr 759 serves as a molecular switch that changes the outcome of the integrin outside-in signals from mediating cell spreading to promoting cell retraction. Furthermore, the switch from cell spreading to retraction is mediated by calpain cleavage of the c-Src binding site at the integrin C terminus, which relieves the c-Src-dependent inhibition of RhoA, and thus facilitates integrin-mediated, RhoA-dependent contractile signaling.
Results

A calpain cleavage-resistant 3 mutant
We have previously reported that the calcium-dependent protease calpain cleaves the cytoplasmic domain of the integrin β 3 A molecular switch that controls cell spreading and retraction subunit mainly at Y 759 , thus removing the C-terminal RGT 762 sequence (Du et al., 1995; Xi et al., 2003) . Calpain cleavage of β 3 is inhibited by tyrosine phosphorylation at Y 759 of the β 3 cytoplasmic domain (Xi et al., 2006) . To understand the physiological role of calpain cleavage of β 3 , we developed a calpain-resistant mutant of β 3 by replacing R 760 with a negatively charged glutamic acid (R760E; Fig. 1 A) . This mutation is intended to mimic the effect of phosphorylation at the adjacent Y 759 by inhibiting calpain cleavage without perturbing the functionally critical NITY motif. The R760E mutant was stably expressed in a CHO cell line (Gu et al., 1999) together with the wild-type (WT) integrin α IIb subunit. To determine whether the R760E mutant confers resistance to calpain-mediated proteolysis, lysates from cells expressing WT integrin α IIb β 3 and the R760E mutant were incubated with or without purifi ed μ-calpain and immunoblotted with Ab762, an antibody recognizing the intact β 3 C-terminal TYRGT 762 sequence, or Ab759, an antibody that recognizes the β 3 TNITY 759 sequence only when β 3 is
cleaved by calpain at Y 759 (Du et al., 1995; Xi et al., 2003) . The specifi cities of these antibodies have been previously characterized in Du et al. (1995) and Xi et al. (2003) . In particular, we have shown that the calpain cleavage-specifi c antibody Ab759 only reacts with the β 3 that is truncated at the C-terminal side of Y 759 and fails to recognize β 3 that is not cleaved (WT) or truncated at different sites, and that Ab762 reacts only with WT β 3 that is not cleaved and fails to react with β 3 cleaved at Y 759 or other sites (Xi et al., 2003) . MAb 15, recognizing the β 3 extracellular domain (which is not disturbed by calpain; Du et al., 1995) , serves as loading control (Fig. 1 B) . WT β 3 shows a large increase in reactivity with Ab759 after treatment with μ-calpain. This increase is mirrored by the loss of reactivity with Ab762, indicating loss of intact C terminus. In contrast, calpaintreated R760E mutant β 3 showed no decrease in Ab762 reaction and dramatically diminished reactivity with Ab759. The relatively low reactivity of Ab762 with the R760E mutant compared with WT β 3 is caused by R 760 to E mutation but is not Figure 1 . A calpain cleavage-resistant mutation of 3 : R760E. (A) WT β 3 cytoplasmic domain sequence and the R760E mutation. (B) Cells expressing WT and R760E mutant α IIb β 3 were solubilized, treated with or without purifi ed μ-calpain, and immunoblotted with anti-β 3 C-terminal antibody Ab762, calpain cleavage-indicator antibody Ab759, and the anti-β3 extracellular domain antibody mAb 15. Note that although R760E showed lower reactivity with Ab762 because of mutation in the epitope (TYR 760 GT), calpain caused minimal loss of Ab762 reactivity or gain of Ab759 reactivity, which indicates calpain resistance. (C) Analysis of stable α IIb β 3 expression in cells expressing WT and R760E mutant integrins, using the monoclonal anti-α IIb β 3 antibody D57. (D) WT and R760E cells spreading on fi brinogen were permeabilized and stained with mAb 15 (green) and purifi ed Ab759 (red). Ab759 staining of R760E cells was reduced compared with WT β 3 . Bar, 10 μm.
caused by reduced R760E expression, as indicated by the reaction with mAb 15. These results demonstrate that R760E mutation is calpain cleavage resistant (Fig. 1 B) . Levels of stable surface expression of the R760E mutant and WT α IIb β 3 were also analyzed by fl ow cytometry to ensure comparable expression after repeated cell sorting with an anti-α IIb β 3 monoclonal antibody, D57 (Fig. 1 C) . We showed previously that the β 3 cytoplasmic domain is cleaved by endogenous calpain in platelets and integrin-expressing CHO cells adherent to fi brinogen (Xi et al., 2003) . To test whether R760E is resistant to endogenous calpain during cell adhesion, CHO cells containing either WT cells or R760E mutant β 3 were allowed to adhere and spread on immobilized fi brinogen and were subsequently immunolabeled with affi nity-purifi ed cleavage-specifi c antibody Ab759 to detect integrin cleavage and with mAb 15 to mark β 3 . WT β 3 was cleaved by calpain (Fig. 1 D) . In contrast, the R760E mutant Figure 2 . Effects of cleavage-resistant 3 mutation, R760E, and calpain inhibition on clot retraction and 3 cleavage. (A) Fibronectin-depleted plasma mixed with WT or R760E cells was induced to coagulate with 2 U/ml thrombin at 37°C for the indicated times, and then photographed. (B) Quantifi cation of clot size at various time points in A. Error bars are the SD from three separate experiments. (C) Clots containing WT or R760E cells were fi xed at 1 h, cryosectioned, stained with purifi ed Ab759 (red) or mAb 15 (green), and observed by confocal microscopy. Note the reduced Ab759 staining of R760E cells. Bars, 10 μm. (D) Clot retraction by WT cells preincubated with either 5 μM of calpain inhibitor MDL 28170 or vehicle control. (E) Quantifi cation of clot sizes in D (mean ± SD). (F) Washed platelets from WT and μ-calpain knockout mice were incubated in an aggregometer with or without 0.1 U/ml thrombin for 7 min. β 3 cleavage at Y 759 , which was detected using cleavage-specifi c antibody Ab759, was enhanced in the WT compared with the calpain knockout. Ab8053 recognizes β 3 extracellular domain and serves as a loading control.
showed marked reduction in calpain cleavage (Fig. 1 D) . Thus, the R760E mutation renders β 3 resistant to cleavage by calpain in cells adherent to fi brinogen. Fibrin clot retraction, mediated by platelets and β 3 integrinexpressing cells, requires β 3 -dependent outside-in signaling and cell retraction (Chen et al., 1994; Law et al., 1996) . To determine whether and how the calpain-resistant mutation of β 3 affects integrin signaling, we compared the ability of the WT β 3 -and R760E-expressing cells to mediate clot retraction (Fig. 2,  A and B) . Clot retraction mediated by R760E cells was signifi cantly decreased (P < 0.001). Consistent with this result, calpain cleaved WT β 3 at Y 759 during clot retraction, and this cleavage was impeded in the R760E mutant cells (Fig. 2 C) . It was previously reported that calpain I knockout platelets showed reduced ability to mediate clot retraction (Azam et al., 2001) . Similarly, a calpain inhibitor, MDL28170, also reduced clot retraction mediated by β 3 integrin-expressing CHO cells (Fig. 2 , D and E). However, the calpain substrate responsible for this effect of calpain was unclear. Thus, our data represent a new fi nding that calpain cleavage of β 3 stimulates clot retraction. This fi nding is consistent with the data obtained in platelets. Although massive integrin cleavage induced by calcium ionophore or high concentrations of thrombin was not signifi cantly affected in calpain I −/− platelets in a previous study (possibly because of the involvement of Calpain II; Azam et al., 2001; Pfaff et al., 1999) , we show in Fig. 2 F that calpain cleavage of β 3 at Y 759 was considerably reduced in calpain I −/− platelets when the cleavage was induced by a lower concentration of thrombin (0.1 U/ml), which is consistent with the fi nding that the calpain I −/− mice were defective in clot retraction when clot retraction was stimulated with a low concentration of thrombin (Azam et al., 2001) .
To determine whether the calpain-resistant β 3 mutant affects integrin-dependent cell spreading, cells expressing WT or R760E mutant α IIb β 3 were allowed to adhere to fi brinogen, and spreading kinetics of these cells were observed (Fig. 3, A and B) . R760E mutation signifi cantly enhanced and accelerated cell spreading compared with WT α IIb β 3 (P < 0.0001), indicating that calpain cleavage of β 3 negatively regulates cell spreading. This result is consistent with the data that cells expressing a deletion mutant of β 3 mimicking calpain cleavage at Y 759 (∆759 cells) are defective in integrin-dependent cell spreading (Fig. 3 E) . Thus, calpain cleavage of β 3 negatively regulates the integrin outside-in signals that promote cell spreading while it stimulates the integrin outside-in signaling that activates cellular retractile machinery. The increase in clot retraction and inhibition of cell spreading by calpain cleavage of β 3 can result either from cleavage-induced activation of cell retractile function or cleavage-induced inhibition of cell spreading signaling. To differentiate these two possibilities, we sought to inhibit the cell retractile signaling mechanisms. Previous studies demonstrate that stress fi ber formation in cells adherent to integrin ligands requires activation of RhoA (Jaffe and Hall, 2003) and Rho-dependent kinases (ROCK), which stimulate myosin light chain phosphorylation Kimura et al., 1996) and thus retractile function of the actomyosin complex (Giuliano et al., 1992) . Indeed, the ROCK inhibitors Y-27632 or H-1152, when preincubated with WT β 3 -expressing CHO cells (Fig. 3 C) and platelets (Fig. 3 D) , impeded clot retraction, indicating that the activation of the RhoA-ROCK signaling pathway is important in integrin-dependent cell retraction. To determine whether this pathway is responsible for calpain cleavage-dependent reversal of the direction of cell membrane movement, we studied the effects of ROCK inhibitors on cell spreading of WT β 3 -expressing or calpain cleavagemimicking β 3 -expressing cells. The CHO cells expressing the calpain-cleaved form of β 3 (∆759) were defective in spreading on fi brinogen, and this defect was completely corrected by the ROCK inhibitors (Fig. 3 E) . Spreading of CHO cells expressing WT α IIb β 3 was not signifi cantly enhanced (P > 0.05) by low concentrations of ROCK inhibitors (Fig. 3, E and F) . However, higher concentrations of either H-1152 or Y-27632 accelerate cell spreading in WT cells (Fig. 3, G and H) . Interestingly, enhancement of spreading by cells expressing cleavageresistant integrin mutant R760E was not observed even with higher-dose ROCK inhibition (Fig. 3, G and H) , suggesting that the inhibitory effect of Rho-kinase signaling on cell spreading is already diminished when β 3 is resistant to calpain cleavage. These results suggest that cleavage of β 3 at Y 759 caused activation of the RhoA-ROCK signaling pathway and cell retraction, thus preventing cell spreading.
Calpain cleavage of 3 at Y 759 induces
RhoA activation
RhoA is activated by GTP binding and inactivated when bound GTP is hydrolyzed to GDP (Jaffe and Hall, 2003) . The Rho binding domain (RBD) of the RhoA effector protein rhotekin specifically binds GTP-bound RhoA and can therefore be used to indicate RhoA activation (Ren and Schwartz, 2000) . To determine whether calpain cleavage of β 3 stimulates RhoA activation, cells were allowed to spread on fi brinogen-coated surfaces, and then were fi xed, permeabilized, and incubated with fl uorescent GST-RBD fusion protein (GST-RBD-555). GST-RBD-555 strongly reacted with the WT integrin-expressing cells spreading on fi brinogen (Fig. 4) . GST-RBD-555 binding was specifi c because it was competitively inhibited by unlabeled GST-RBD (Fig. 4 A) and by preincubation of cells with cell-permeable C3 transferase ( Fig. 5 ) but was unaffected in the presence of 20 mM glutathione (Fig. 4 A) . The specifi city of GST-RBD-555 is further supported by its colocalization with the stain of a monoclonal antibody that recognizes RhoA (Fig. 4 B) . Thus, by using this novel in situ RhoA activation assay, we show that RhoA is activated after WT integrin-mediated cell adhesion and spreading on fi brinogen. In contrast to WT β 3 , cells expressing the calpain-resistant β 3 mutant R760E display reduced reactivity with GST-RBD-555, indicating that the resistance to calpain cleavage by R760E mutation and increased cell spreading in R760E cells are associated with inhibition of integrin-induced RhoA activation. Conversely, ∆759 cells, which are defective in spreading on fi brinogen, showed robust reactivity with GST-RBD-555, indicating that the calpain-cleaved form of β 3 induces RhoA activation without requiring cell spreading.
Collectively, these data demonstrate that cleavage of β 3 at Y 759 switches on the RhoA-ROCK signaling pathway, leading to cell retraction and inhibition of cell spreading.
Effects of calpain cleavage-resistant or -mimicking mutations on c-Src binding to 3
It has been reported that a member of the Src family of protein kinases (SFK), c-Src, interacts with the β 3 cytoplasmic domain and that this interaction requires the YRGT 762 sequence in the C terminus of β 3 (Arias-Salgado et al., 2005a,b) . To determine whether c-Src interaction with β 3 is affected by the R760E mutation or calpain cleavage-mimicking truncation of β 3 , WT and mutant β 3 , stably expressed in CHO cells, were immunoprecipitated with Ab8053, an anti-β3 antibody, and precipitates were immunoblotted for β 3 -associated c-Src (Fig. 6) . We found that c-Src coimmunoprecipitated with both WT and R760E mutant forms of β 3 but failed to interact with the cleavage-mimicking mutant ∆759 (Fig. 6 ). These data are consistent with previous studies (Arias-Salgado et al., 2005a,b) , indicating that cleavage of the β 3 C-terminal RGT sequence disrupts c-Src binding to β 3 .
Calpain cleavage of 3 at Y 759 relieves the inhibitory effect of c-Src on RhoA activation and thus promotes cell retraction
It has been shown that c-Src plays an important role in cell spreading (Kaplan et al., 1995) and that c-Src interaction with β 3 is important for this function (Arias-Salgado et al., 2003; Shattil, 2005) . Therefore, we examined whether the loss of β 3 -associated c-Src function is responsible for the activation of cell retraction and inhibition of cell spreading induced by calpain cleavage at Y
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The inhibitory effect of PP2 bears striking resemblance to the defi ciency in cell spreading in ∆759 cells. More importantly, the inhibitory effect of PP2 was reversed by ROCK inhibitors H-1152 and Y-27632, indicating that the RhoA-ROCK-mediated retractile signaling is required for the inhibitory effect of this SFK inhibitor on cell spreading (Fig. 7, A and D) , which is similar to the requirement for ROCK in β 3 cleavage-mediated inhibition of cell spreading. To exclude the possible nonspecifi c effect of pharmacological inhibitors, WT β 3 -expressing cells were transfected with cDNA, encoding a dominant-negative mutant of c-Src (K295R/Y527F; Mukhopadhyay et al., 1995) , and cotransfected with 1/6 quantity of GFP cDNA to indicate successful transfection. The control cells expressing transfected GFP exhibited normal cell spreading on fi brinogen (Fig. 7, B and E). In contrast, the cells transfected with the dominant-negative c-Src showed a defect in cell spreading similar to that caused by PP2 (Fig. 7, B and D) . This inhibitory effect of the dominant-negative c-Src was reversed when cells were cotransfected with an equal concentration of dominant-negative RhoA (N19-RhoA; Fig. 7 , B and D; Qiu et al., 1995) . The data obtained with cDNA transfection is thus consistent with the data using inhibitors of SFK and ROCK, indicating that integrin-dependent cell spreading occurs independent of c-Src when RhoA-mediated retractile signaling is disabled.
Because integrin-mediated c-Src activation inhibits RhoA but does not affect cdc42 and Rac functions (Arthur et al., 2000) , our data indicate that c-Src promotes integrin-dependent cell spreading by its inhibition of RhoA-mediated retractile signals. Furthermore, the SFK inhibitor PP2 corrected the defective RhoA activation in calpain cleavage-resistant R760E cells, restoring RhoA activation and inhibiting the spreading of R760E cells (Fig. 7, C and F) , which is similar to the phenotype observed in ∆759 cells expressing the calpain-cleaved form of β 3 . These results indicate that without calpain cleavage of β 3 , β 3 -dependent c-Src activity inhibits RhoA activation and thus promotes cell spreading. Conversely, inhibition of SFK with PP2 dramatically enhanced clot retraction (Fig. 7 G) , further demonstrating that SFK inhibits cell retractile machinery. Therefore, cleavage of β 3 at Y 759 relieves the inhibitory effect of c-Src on RhoA activation, switches on RhoA-ROCK-dependent cell retraction, and thus changes the functional outcome of integrin signaling from cell spreading to cell retraction. Figure 5 . Inhibition of GST-RBD binding to active RhoA by cell-permeable C3 transferase. Cells expressing WT α IIb β 3 were preincubated with or without 5 μg/ml of cell-permeable C3 transferase and were allowed to spread on fi brinogencoated surfaces for 1 h. Cells were stained with GST-RBD-555 (red) to detect active RhoA and with mAb 15 (green) to mark integrin surface expression. Bars, 10 μM. Previous studies suggested that activity of c-Src associated with β 3 is increased compared with that of c-Src that is not associated with β 3 (Arias-Salgado et al., 2005a) . To investigate the possibility that cleavage of β 3 at Y 759 regulates integrin-dependent overall c-Src activation in adherent cells, we measured the amount of active c-Src in CHO cells expressing WT and calpain cleavage-resistant (R760E) and -mimicking (∆759) mutants of β 3 . All three cell lines were similarly capable of inducing considerable c-Src phosphorylation at Y 416 (an indicator of c-Src activation) when allowed to adhere and spread onto fi brinogencoated surfaces (Fig. 8 A) , suggesting that deletion of the c-Src binding site in β3 did not affect the overall integrin-mediated c-Src activation. Furthermore, if c-Src activity alone was sufficient to mediate the inhibition of RhoA, constitutively active c-Src would be able to induce integrin-mediated cell spreading. Thus, ∆759 cells were transfected with cDNA encoding a constitutively active mutant of c-Src (E378G) and cotransfected with 1/6 quantity of GFP cDNA to indicate successful transfection. Increased levels of total c-Src and expression of constitutively active c-Src (Y 416 phosphorylated) in E378G c-Src-transfected ∆759 cells in suspension were verifi ed by Western blot (Fig. 8 B) .
The E378G c-Src-transfected ∆759 cells are not different from the GFP-expressing control ∆759 cells in that both spread poorly on fi brinogen (Fig. 8, C and D) . These data suggest that the inhibitory effect of β 3 cleavage on cell spreading is not because of its effect on overall c-Src activation but is associated with dissociation of c-Src (and therefore c-Src activity) from the β 3 cytoplasmic domain. Thus, only the β 3 -associated c-Src activity is responsible for mediating RhoA inhibition and promoting cell spreading. Collectively, our results strongly suggest that cleavage of β 3 at Y 759 dissociates c-Src from the β 3 C-terminal domain and thus relieves the inhibitory effect of β 3 -associated c-Src on RhoA activation, stimulating the RhoA-ROCK retractile signals, which switches the functional outcome of integrin signaling from mediating cell spreading to promoting cell retraction.
Discussion
In this study, we have discovered that β 3 cleavage by calpain serves as a molecular switch that changes the outcome of integrin outside-in signaling from mediating cell spreading to promoting cell retraction. The switch in the outcome of integrin signaling from cell spreading to retraction is mediated by β 3 cleavage-dependent activation of the RhoA retractile signaling pathway, and β 3 cleavage-dependent activation of the RhoA signaling pathway is mediated by cleavage-dependent relief of the inhibitory effects of β 3 -associated c-Src on the RhoA signaling pathway. Thus, our study also reveals that the requirement of SFK in integrin-dependent cell spreading is caused by its inhibition of the RhoA-dependent retractile function of the cell. These new fi ndings represent major conceptual advances in our understanding of how integrin signaling controls and regulates the direction of cell membrane movement.
The data supporting our conclusions in this study are mainly obtained using the reconstituted integrin signaling model in CHO cells expressing WT and calpain cleavage-resistant or -mimicking mutants of β 3 . Integrins play critical roles in all mammalian cells that adhere to extracellular matrix. Although different cell types express different members of the integrin family, integrin signaling, particularly outside-in signaling, is generally conserved in adherent cells, including CHO cells. In the past 20 yr, many important fi ndings in β 3 integrin function and signaling have been discovered using the CHO cell model expressing the WT and mutant β 3 integrins, including the fi nding of the important role of talin in integrin activation (O'Toole et al., 1990; Calderwood et al., 1999; Tadokoro et al., 2003; Xi et al., 2003) . Furthermore, the results obtained in CHO cells have been consistently verifi ed in native β 3 -expressing cells, such as platelets (Li et al., 2001 (Li et al., , 2003a (Li et al., , 2006 Tadokoro et al., 2003; Zou et al., 2007) , indicating the validity of the CHO cell model. Importantly, the data obtained in CHO cell models in this study are consistent with the role of calpain I in clot retraction and in β 3 cleavage as indicated in experiments using human and mouse platelets. Nevertheless, it is recognized that CHO cells are not totally identical to native β 3 -expressing cells such as platelets, and thus the results obtained with the CHO cell model will need to be further verifi ed in platelets and other β3-expressing cells in the future.
We have previously shown that the cytoplasmic domain of β 3 is a calpain substrate and that the cleavage occurs mainly at Y 759 , removing the C-terminal RGT sequence (Du et al., 1995; Xi et al., 2003) . However, although calpain is activated after calcium elevation is induced by ligand binding to the integrin, very little cleavage of β 3 occurs early during cell spreading because of the protection of integrin from calpain cleavage by tyrosine phosphorylation of the β 3 cytoplasmic domain, especially at the periphery of a cell (Xi et al., 2006) . In contrast, at a later time during cell spreading when Y 759 of β 3 becomes dephosphorylated, substantial β 3 cleavage occurs (Xi et al., 2006) . Also, calpain cleavage of β 3 is readily detectable both during clot retraction in platelets and in the β 3 -expressing CHO cells. The kinetics of integrin cleavage are consistent with our data, indicating a role for calpain in the transition between cell spreading and cell retraction in both CHO cells and in platelets. In fact, the data obtained with cells expressing the calpain-resistant and calpain cleavage-mimicking mutants clearly reveal that cleavage of β 3 at Y 759 generates the change in integrin signaling from mediating cell spreading to promoting cell retraction. Thus, we have discovered a calpain-dependent molecular switch that is regulated temporally and topographically by tyrosine phosphorylation of β 3 and that controls the direction of membrane and cytoskeleton movement induced by integrin outside-in signaling.
It is important to note that the cleavage-mimicking mutant of β 3 creates an experimental condition where 100% of β 3 cytoplasmic domain is cleaved at Y 759 , which serves to clearly reveal the cleavage-induced changes in functional outcome. In platelets, >22% of β 3 is cleaved at Y 759 within an hour after platelet activation (Xi et al., 2003) , which coincides with the occurrence of marked clot retraction. However, in more delicate situations, such as during cell spreading and migration, local and dynamic calpain activation signals are likely to cause localized cleavage of a small percentage of β 3 molecules and thus dynamically control the local movement of membranes and cytoskeleton.
The β 3 cleavage-mediated inhibition of cell spreading and promotion of cell retraction is not caused by its inhibition of cell spreading mechanisms but is mediated by the integrin cleavage-dependent activation of the RhoA retractile signaling pathway. Previous studies suggest that Rac and cdc42 play important roles in mediating cell spreading (fi lopodia and lamellipodia formation) and that RhoA is increasingly activated in spread cells (Hall, 2005) . RhoA activates ROCK, which phosphorylates and inactivates myosin light chain phosphatase, and enhances myosin light chain phosphorylation and retractile function of the actomyosin complex (Giuliano et al., 1992; Amano et al., 1996; Kimura et al., 1996) , inducing cell retraction. Cleavage of β 3 at Y 759 inhibits integrin-mediated cell spreading ( Fig. 3 ; Xi et al., 2003) . If the inhibitory effects of β 3 cleavage on cell spreading should result from its inhibition of Rac-and cdc42-mediated cell spreading signaling, this inhibitory effect should not be corrected by inhibition of RhoA pathway. Therefore, our data that β 3 cleavage-dependent inhibition of cell spreading is corrected by ROCK inhibitors indicate that calpain cleavage of β 3 activates RhoA-dependent cell retraction, which subsequently inhibits the opposite movement of cell membrane resulting in inhibition of cell spreading.
Previous studies indicate that members of SFK are required for integrin-mediated signaling that leads to cell spreading (Shattil, 2005) . The mechanism responsible for this role of SFK is not clear but is believed to be an early step in cell spreading signaling. However, we show that the inhibitory effect of an SFK inhibitor and a dominant-negative c-Src mutant on β 3 -mediated cell spreading is reversed by inhibition of the RhoA signaling pathway, indicating that cell spreading is independent of c-Src when RhoA signaling is abrogated. These data therefore provide the fi rst direct evidence that the role of SFK in promoting integrin-dependent cell spreading is not that it is required for cdc42-and Rac-dependent cell spreading signaling, but rather is its inhibition of RhoA-dependent retractile signaling and thus cell retraction, which confi nes the outward movement of the cell membrane and cytoskeleton. Our data are consistent with the previous studies, which show that SFK inhibits RhoA activity but has no effect on the activity of cdc42 and Rac (Arthur et al., 2000) . Our data are also consistent with the fi nding that RhoA inactivation by p190RhoGAP promotes membrane protrusion and polarity (Arthur and Burridge, 2001 ). More importantly, we show that cleavage of β 3 at Y 759 abolishes c-Src binding to β 3 but does not signifi cantly affect overall c-Src activation in cells spread on fi brinogen, and that the RhoA-dependent inhibition of cell spreading by β 3 cleavage at Y 759 is not reversed by expression of a constitutively active Src. These data suggest that whereas overall intracellular c-Src activation during cell adhesion does not require c-Src association with β 3 , active c-Src molecules dissociated from β 3 are not capable of inhibiting the RhoA signaling pathway and promoting cell spreading on β 3 ligands, possibly because of the lack of β 3 scaffold. However, the calpain cleavage-resistant mutation in β 3 inhibits RhoA activation in a Src-dependent manner. Thus, our results suggest that only the β 3 -associated c-Src is responsible for the inhibition of the RhoA pathway and facilitation of cell spreading. Conversely, our results suggest that calpain cleavage of β 3 , which abolishes Src binding to β 3 ( Fig. 6 ; Arias-Salgado et al., 2005b) , relieves the inhibitory effects of β 3 -associated c-Src on the RhoA pathway, activates RhoA, and thus switches the outcome of integrin signaling from cell spreading to retraction.
Interestingly, β 3 cleavage-dependent relief of c-Srcmediated RhoA inhibition and activation of RhoA-dependent cell retraction is associated with the cleavage of only a fraction of β 3 molecules ( Fig. 2 ; Xi et al., 2003) and cannot be prevented by the presence of uncleaved β 3 molecules in the same cell. This apparently dominant effect of β 3 cleavage suggests that c-Src activity at one location in a cell does not cross-inhibit RhoA activation induced by calpain cleavage of β 3 at a different location and is consistent with the knowledge that spreading (such as fi lopodia and lamellipodia) and retraction can occur simultaneously at different locations within a cell (such as during cell migration). The requirement of c-Src association with β 3 for the c-Src-mediated RhoA inhibition provides a mechanism for the localized role of c-Src in promoting cell spreading. Further studies are required to understand how β 3 -associated c-Src activity locally regulates RhoA and whether additional mechanisms are needed for RhoA activation when β 3 cleavage by calpain relieves the inhibitory effect of β 3 -associated c-Src.
Based on data from this and other studies, we propose a new model of integrin signaling that incorporates a phosphorylation-and protease-mediated mechanism regulating integrinmediated cell membrane movements. In this model (Fig. 9) , initial integrin signaling activates protein tyrosine kinases, which induce phosphorylation of the cytoplasmic domain of β 3 (Law et al., 1996 (Law et al., , 1999 , and elevates intracellular calcium levels, which activate calpain (Fox et al., 1993) . Tyrosine phosphorylation at Y 759 of β 3 in the early phase of cell spreading protects the c-Src binding site in the C-terminal domain of β 3 from calpain cleavage (Xi et al., 2006) . The interaction of c-Src with β 3 promotes activation of β 3 -associated c-Src by a Csk- (Obergfell et al., 2002) and protein tyrosine phosphatase IBdependent mechanism (Arias-Salgado et al., 2005a) and/or allows c-Src-dependent signaling in the vicinity of the β 3 C terminus, which facilitates cell spreading by inhibiting RhoA-dependent cell retraction. In spread cells, Y 759 of β 3 becomes dephosphorylated (Xi et al., 2006) , allowing β 3 cleavage by activated calpain, which removes the C-terminal RGT sequence of β 3 important in c-Src binding. Integrin cleavage by calpain thus relieves the local inhibitory effect of β 3 -associated c-Src on the RhoA-ROCK signaling pathway and locally activates RhoAdependent cell retractile signals (Xi et al., 2003; Arias-Salgado et al., 2005b) . Thus, calpain cleavage of β 3 switches the direction of integrin outside-in signaling from mediating spreading to promoting cell retraction. 
Materials and methods
Reagents
Plasma containing 0.38% sodium citrate and 40 μg/ml aprotinin (SigmaAldrich) was depleted of fi bronectin as previously reported in Chen et al. (1994) . Ab762 and Ab759 were previously described in Du et al. (1995) and Xi et al. (2003) . mAb 15, D57, and Ab8053 were provided by M. Ginsberg (University of California, San Diego, La Jolla, CA; O'Toole et al., 1990) . Phosphospecifi c anti-Src Y 416 antibody was obtained from Cell Signaling; anti-RhoA and cell permeable C3 transferase were obtained from Cytoskeleton, Inc.; Sudan black was obtained from Sigma-Aldrich; Alexa Fluor 594-conjugated goat anti-rabbit IgG and Alexa Fluor 488-conjugated goat anti-mouse IgG were obtained from Invitrogen; anti-v-Src monoclonal antibody, SFK inhibitor PP2, ROCK inhibitors H-1152 and Y-27632, and calpain inhibitor MDL 28170 were obtained from Calbiochem; and an anti-c-Src polyclonal antibody was obtained from Santa Cruz Biotechnology, Inc. GST-RBD cDNA were a gift from T. Kozasa (University of Illinois, Chicago, IL). GST-RBD fusion protein was purifi ed as previously described in Ren and Schwartz (2000) . Purifi ed protein was fl uorescently labeled with an Alexa Fluor 555 microscale protein labeling kit (Invitrogen).
Construction of R760E mutant
The β 3 R760E mutation was performed using PCR. The forward primer has the sequence of A G A
G C T T A A G G A C A C . The reverse primers (C T C A T T A A-G T C C C C T C G T A G G T G A T A T T G G ) contain an
XhoI digestion site, stop codon, and the 18-nucleotide C-terminal β 3 sequence coding the intended R760E mutation. PCR products were digested with AspI and XhoI and ligated into a β 3 cDNA construct in a modifi ed cDM8 vector containing only one XhoI site at the 3′ end of the multiple cloning site. The construct was verifi ed by DNA sequencing.
Cell lines and transfection
CHO cells stably expressing WT human α IIb β 3 (2b3a), human glycoprotein Ib-IX (GPIb-IX; 1b9), or both α IIb β 3 and GPIb-IX (123) were previously described in Gu et al. (1999) and Xi et al. (2003) . CHO cells expressing GPIb-IX and a truncation mutant β 3 , mimicking calpain cleavage at Y 759 , and complexed with WT α IIb (∆759) were also described previously in Gu et al. (1999) and Xi et al. (2003) . DNA transfection was performed using Lipofectamine 2000 (Invitrogen). R760E β 3 mutant cDNA was cotransfected with WT α IIb and pcDNA 3.1/Hyg plasmid at a ratio of 5:5:1 into 1b9 cells. Complex formation between α IIb and β 3 subunits was verifi ed by fl ow cytometry using antibody D57 against α IIb β 3 complex. Stable R760E mutant cell lines were obtained by antibiotic selection and repeated cell sorting using D57 as previously described (Gu et al., 1999) . To ensure comparable expression, R760E and ∆759 cells were sorted using the expression level of the stable WT α IIb β 3 -expressing (123) cells as a gate (Gu et al., 1999; Xi et al., 2003) . For transient transfections, cells stably coexpressing WT α IIb β 3 were transfected with either 2 μg GFP, 2 μg GFP plus 12 μg of dominant-negative c-Src (Mukhopadhyay et al., 1995) , 2 μg GFP plus 12 μg of dominant-negative N19-RhoA (Qiu et al., 1995) , or 2 μg GFP plus 12 μg of both dominant-negative c-Src and N19-RhoA, using Lipofectamine 2000. In some experiments, cells were transiently transfected with either 2 μg GFP or 2 μg GFP plus 12 μg of constitutively active c-Src (E378G). Cells were analyzed 24 h after transfection.
Calpain cleavage of 3 in CHO cells and mouse platelets 10 7 CHO cells were directly solubilized in buffer containing 2% Triton X-100, 0.15 M NaCl, 1 mM CaCl 2 , and 0.02 M Tris, pH 7.4, in the presence or absence of 10 mM EDTA. Cell lysates were incubated for 40 min at 37°C with or without 1 μg of purifi ed μ-calpain. SDS-PAGE sample buffer containing 10 mM EDTA, 1 mM PMSF, and 0.2 mM E64 was added to stop reactions. For experiments using mice, 6-8-wk-old mice of either sex were anesthetized by intraperitoneal injection of pentobarbital and blood was drawn from the inferior vena cava. Blood from 5-6 (calpain I +/+ and calpain I −/− ; Azam et al., 2001) mice was pooled or platelets were isolated by differential centrifugation as described in Li et al. (2003b) . 3 × 10 8 /ml washed platelets were resuspended in modifi ed Tyrode's buffer (Du et al., 1991) and incubated at 22°C for 2 h before use. Platelets were stimulated with 0.1 U/ml thrombin in a platelet aggregometer at 37° for 7 min, and then solubilized in SDS-PAGE sample buffer. All samples were analyzed by SDS-PAGE using 4-15% gradient gels and were immuno blotted using various antibodies. Enhanced chemiluminescence (GE Healthcare) was used for visualization of antibody reactions.
Immunofl uorescence and confocal microscopy Chamber slides (Lab-Tek; Nunc) were precoated with 10 μg/ml fi brinogen and blocked with 5% BSA in PBS. 50 μl CHO cells (expressing WT or mutant integrins; 5 × 10 5 /ml) in Tyrode's buffer was added to the wells and incubated at 37°C for 1 h. After washing, cells were fi xed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100, 0.1 M Tris, 10 mM EGTA, 0.15 M NaCl, 5 mM MgCl 2 , 1 mM PMSF, 0.1 mM E64, and 1% BSA (permeabilization buffer, pH 7.5). Samples were blocked with 5% BSA, incubated with 10 μg/ml mAb 15 and 0.5 μg/ml of purifi ed Ab759, and, after washing, stained with fl uorescently labeled secondary antibodies. To detect RhoA activation, cells were fi xed in 4% paraformaldehyde in PBS with 10 mM MgCl 2 and incubated with 0.7 μg/ml mAb 15 and Alexa Fluor 555-labeled GST-RBD in permeabilization buffer containing 10 mM MgCl 2 . After further staining with Alexa Fluor 488-conjugated goat anti-mouse IgG and washes, the antibody and GST-RBD staining were detected using a confocal microscope (Carl Zeiss MicroImaging, Inc.). In some experiments, cells were also preincubated with or without 5 μg/ml of cell-permeable C3 transferase to inhibit RhoA, according to the manufacturer's instructions, and then stained with GST-RBD-555. Surface area in spreading cells was estimated by measuring total pixel number per cell in digitally recorded images using Image J software (National Institutes of Health). Quantitation of 555-nm fl uorescence in R760E cells was determined by using the area tool in LSM 5 software (Carl Zeiss MicroImaging, Inc.) and expressed as total pixel number. Statistical signifi cance was determined using a t test.
Clot retraction 400 μl of indicated CHO cell lines (4 × 10 6 /ml), in complete DME in the presence or absence of 5 μM ROCK inhibitors H-1152 or Y-27632 or calpain inhibitor MDL 28170, was mixed with 100 μl of plasma, 2 U/ml thrombin, and 5 mM CaCl 2 in a partially Sigmacote-treated glass cuvette (Chrono-Log). For platelet samples, citrated platelet-rich plasma was mixed with 0.2 U/ml thrombin. The clots were allowed to retract at 37°C and were photographed at various times. The two-dimensional sizes of retracted clots on photographs were quantifi ed using Image J software and were expressed as clot size. Statistical signifi cance was determined using a t test.
Confocal microscopy analysis of clot sections
Clots were fi xed with 4% paraformaldehyde, embedded in 50% Tissue-Tek OCT compound (Sakura Finetek), placed in 25 × 20 × 5-mm Tissue-Tek Cryomolds (Sakura Finetek), and snap frozen in liquid nitrogen. Frozen sections were made using a cryostat microtome (Microm HM 505 E; Carl Zeiss MicroImaging, Inc.). Slides were then washed and quenched with 5% Sudan black (wt/vol) in 70% ethanol. Sections were permeabilized with 0.1% Triton X-100, 0.1 M Tris, 10 mM EGTA, 0.15 M NaCl, 5 mM MgCl 2 , 1 mM PMSF, 0.1 mM E64, and 1% BSA, pH 7.5 (permeabilization buffer), blocked with 5% BSA, and immunolabeled with 10 μg/ml mAb 15 and 0.5 μg/ml of purifi ed Ab 759. After washing, cells were stained with Alexa Fluor 594-conjugated anti-rabbit IgG and 488-conjugated antimouse IgG. Data was collected using a confocal microscope.
Spreading assays
CHO cells expressing WT, R760E mutant, and ∆759 mutant integrins (100 μl/well, 1.5 × 10 5 /ml) in complete DME were incubated in fi brinogencoated chamber slides at 37°C for 20, 40, and 60 min. At each time, cells were immediately rinsed and fi xed with 4% paraformaldehyde. For assays using PP2 and ROCK inhibitors, cells were preincubated at 22°C for 30 min with or without 10 μM PP2 and/or 4 μM H-1152 or Y-27632. Cells were allowed to spread for 1 h at 37°C, rinsed, and fi xed with 4% paraformaldehyde. Images were captured using a microscope (DM IRB; Leica). The size of the cells from four random fi elds for each time and cell line was determined using Image J software. Relative increase in cell size was calculated by dividing the mean size of spread cells by the mean size of suspended cells from each cell line. Statistical signifi cance was determined using a t test.
Immunoprecipitation
Cells were lysed in lysis buffer containing 1% NP-40, 150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM sodium orthovanadate, 1 mM NaF, and Complete protease inhibitor mixture (Roche Molecular Biochemicals). Lysates were incubated with either rabbit anti-β 3 or an equal amount of rabbit IgG and subsequently with protein A-Sepharose (GE Healthcare). Beads were washed four times with lysis buffer, analyzed by SDS-PAGE using 4-15% gradient gels, and immunoblotted with mAb 15 for β 3 and monoclonal anti-Src (Calbiochem).
Immunoblot analysis of c-Src activation in cells adherent on fi brinogen-coated surfaces 10-cm polystyrene dishes (Fisher Scientifi c) were coated with 10 μg/ml fi brinogen and blocked with 5% BSA in PBS. Equal suspensions containing 5 × 10 6 CHO cells stably expressing WT, R760E mutant, or ∆759 mutant integrins in modifi ed Tyrode's buffer were either kept in suspension or added to the dishes and incubated at 37°C for 30 min. Plates were rinsed three times with PBS and cells were subsequently lysed with the buffer containing 1% NP-40, 150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM sodium orthovanadate, 1 mM NaF, and Complete protease inhibitor mixture. Lysates were analyzed by SDS-PAGE using 4-15% gradient gels, and then immunoblotted with anti-phospho-Src Y 416 and anti-c-Src.
